- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
- Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
- Rezolute Reports First Quarter Fiscal 2024 Results
- Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
More ▼
Key statistics
On Friday, Rezolute Inc (RZLT:NAQ) closed at 2.66, -27.91% below its 52-week high of 3.69, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.65 |
---|---|
High | 2.71 |
Low | 2.54 |
Bid | 2.67 |
Offer | 2.72 |
Previous close | 2.60 |
Average volume | 472.73k |
---|---|
Shares outstanding | 40.13m |
Free float | 32.02m |
P/E (TTM) | -- |
Market cap | 104.33m USD |
EPS (TTM) | -1.11 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼